News – 2020

Hummingbird Bioscience is collaborating with Tempus to advance HMBD-001, a differentiated anti-HER3 neutralizing antibody developed using Hummingbird’s Rational Antibody Discovery platform, into clinical trials in HER3-driven cancers, including those that harbor neuregulin 1 (NRG1) fusions. Read the full story on BioWorld.

Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing revolutionary therapies for hard-to-drug targets, today announced a collaboration with Tempus, a leader in artificial intelligence and precision medicine, to drive the development of Hummingbird’s lead clinical program, HMBD-001, as it advances into clinical trials in HER3-driven cancers, including those that harbor neuregulin 1 (NRG1) fusions.

A new Covid-19 treatment could become available in Singapore and beyond by early 2021 as homegrown biotech company Hummingbird Bioscience joins major names in making steps to combat the coronavirus.

SARS-CoV-2-neutralizing antibodies are promising therapeutics for COVID-19. However, little is known about the mechanisms of action of these antibodies.

Global business has faced unprecedented challenges over the past 12 months, particularly in 2020.

The Parker Institute for Cancer Immunotherapy (PICI) announced today that John Connolly, Ph.D., has been named chief scientific officer (CSO). In this role, Connolly.